Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced today the first patient enrollment in the QUADRA-PE study (NCT06672510) ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Eko Health has been advancing the use of artificial intelligence to help providers detect the early signs of disease, ...
Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...
F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...
Akura Medical begins patient enrollment in QUADRA-PE study of Katana Thrombectomy System to treat acute pulmonary embolism: Los Gatos, California Thursday, February 6, 2025, 18:00 ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
Pulmonary artery pressure monitoring systems use sensors to collect data on pulmonary artery pressure in people with chronic heart failure to allow for ongoing remote monitoring. A pulmonary artery ...
PAH is a progressive and life-threatening disease in which the blood pressure ... time, we found that after PAH-targeted therapy, the uptake of 18 F-FAPI in the right heart and pulmonary artery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback